Annexon, Inc. · NASDAQ:ANNX
Annexon — Technical Presentation (June 2024)
9 slides from Annexon's technical presentation, Jun 23, 2024
Slide 1: Comparative Efficacy: Potential Advantage of ANX005 over IVIg in Guillain-Barré Syndrome
Comparative Efficacy: Potential Advantage of ANX005 over Intravenous Immunoglobulin in Guillain-Barré Syndrome Henk-André Kroon, MD MBA Annexon Biosciences Inc., Brisbane, USA Poster 237 1 PROPRIETARY and CONFIDENTIAL
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward‐looking” statements about Annexon, Inc. and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts, including statements regarding our clinical and preclinical programs, ti
Slide 3: Disclosures
Disclosures Henk-André Kroon, MD MBA Employee of Annexon Biosciences ANX005 for GBS Granted FDA Fast Track and FDA / EMA Orphan Drug Designation Visit us at Poster 237 or Annexon Lunch Symposium – Room 710b – Tuesday 25 June starting 12.45 PM 3
Slide 4: Introduction
Introduction 1. In GBS, auto antibodies cross-react with the peripheral ACUTE ACTIVE PHASE RECOVERY PHASE nervous system, and activate the classical complement pathway causing nerve inflammation and nerve damage 2. With IVIg, ~25% of patients show progressive muscle Paralysis weakness, resulting in
Slide 5: Indirect Comparisons of ANX005 Anti-C1q Therapy to IVIg
Indirect Comparisons of ANX005 Anti-C1q Therapy to IVIg 1 ANX005 • 1 ANX005 Phase 1b study of GBS patients from Bangladesh was used in an indirect comparison to data from two studies of IVIg-treated GBS patients in 2 different populations: 2 IGOS (Bangladesh) 3 SID-GBS (Netherlands) Placebo IVIg •
Slide 6: ANX005 Showed Rapid Improvement in Muscle Strength over IVIg
ANX005 Showed Rapid Improvement in Muscle Strength over IVIg Significant early benefit seen with ANX005 versus IVIg in Bangladesh Similar Baseline Muscle Strength Significant Improvement at Week 1 p=0.008 Median MRC Change from Baseline Median Median MRC at Baseline ANX005-BGD IVIg IGOS-BGD ANX005-B
Slide 7: ANX005 Shift to Better vs IVIg: Improved Function at Week 4
ANX005 Shift to Better vs IVIg: Improved Function at Week 4 Odds ratio of 2.5, adjusted for baseline GBS-DS ANX005 18-75 mg/kg N=18 IGOS Bangladesh IVIg N=13 OR 2.5 (95% CI: 0.6-10), p=0.19 7
Slide 8: Conclusion
Conclusion • In a previously presented Phase 1b study ANX005 showed evidence of early improvement in muscle strength and better health status at week 8 versus placebo • In a matched population treated with IVIg in Bangladesh, ANX005 showed the potential to be better than IVIg with early improvement
Slide 9: Thank You! Q&A
Thank You! Q&A Annexon Biosciences sincerely thanks all the patients, families, and study staff who are helping make the ANX005 GBS Program possible 9